Connection

Brent Egan to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Brent Egan has written about Cardiovascular Diseases.
Brent Egan
Connection Strength
5.261
Cardiovascular Diseases
  1. Sociodemographic Determinants of Life's Simple 7: Implications for Achieving Cardiovascular Health and Health Equity Goals. Ethn Dis. 2020; 30(4):637-650.
    View in: PubMed
    Score: 0.425
  2. Differences in primary cardiovascular disease prevention between the 2013 and 2016 cholesterol guidelines and impact of the 2017 hypertension guideline in the United States. J Clin Hypertens (Greenwich). 2018 06; 20(6):991-1000.
    View in: PubMed
    Score: 0.361
  3. Trends in Prehypertension and Hypertension Risk Factors in US Adults: 1999-2012. Hypertension. 2017 08; 70(2):275-284.
    View in: PubMed
    Score: 0.339
  4. Opportunities for improving cardiovascular health outcomes in adults younger than 65?years with guideline-recommended statin therapy. J Clin Hypertens (Greenwich). 2017 Sep; 19(9):850-860.
    View in: PubMed
    Score: 0.336
  5. Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension. J Clin Hypertens (Greenwich). 2016 08; 18(8):817-24.
    View in: PubMed
    Score: 0.309
  6. Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network. Ther Adv Cardiovasc Dis. 2016 Apr; 10(2):56-66.
    View in: PubMed
    Score: 0.307
  7. Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community-Based Practice Registry. J Clin Hypertens (Greenwich). 2016 07; 18(7):663-71.
    View in: PubMed
    Score: 0.304
  8. Impacting population cardiovascular health through a community-based practice network: update on an ASH-supported collaborative. J Clin Hypertens (Greenwich). 2011 Aug; 13(8):543-50.
    View in: PubMed
    Score: 0.225
  9. Sodium intake and mortality: the debate continues. J Gen Intern Med. 2008 Sep; 23(9):1537-8.
    View in: PubMed
    Score: 0.184
  10. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005 Jul; 7(7):409-16.
    View in: PubMed
    Score: 0.148
  11. Prehypertension and cardiovascular morbidity. Ann Fam Med. 2005 Jul-Aug; 3(4):294-9.
    View in: PubMed
    Score: 0.148
  12. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol. 2004 Dec 15; 94(12):1496-500.
    View in: PubMed
    Score: 0.143
  13. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):18-25.
    View in: PubMed
    Score: 0.133
  14. The role of sympathetic activation in cardiovascular disease. Postgrad Med. 2003 Dec; 114(6 Suppl Role):4-10.
    View in: PubMed
    Score: 0.133
  15. Other important applications for beta-blockers in high-risk patients. Postgrad Med. 2003 Dec; 114(6 Suppl Role):35-48.
    View in: PubMed
    Score: 0.133
  16. Cardiovascular risk factor control and treatment patterns in primary care. Manag Care Interface. 2003 Nov; 16(11):21-6.
    View in: PubMed
    Score: 0.132
  17. Insulin resistance and cardiovascular disease. Am J Hypertens. 2001 Jun; 14(6 Pt 2):116S-125S.
    View in: PubMed
    Score: 0.112
  18. Nonesterified fatty acids in blood pressure control and cardiovascular complications. Curr Hypertens Rep. 2001 Apr; 3(2):107-16.
    View in: PubMed
    Score: 0.110
  19. The hypertension initiative of South Carolina. Promoting cardiovascular health through better blood pressure control. J S C Med Assoc. 2001 Feb; 97(2):57-62.
    View in: PubMed
    Score: 0.109
  20. Efficacy of a church-based intervention on cardiovascular risk reduction. Ethn Dis. 2001; 11(4):817-22.
    View in: PubMed
    Score: 0.108
  21. Short-term impact of a church-based approach to lifestyle change on cardiovascular risk in African Americans. Ethn Dis. 2000; 10(1):17-23.
    View in: PubMed
    Score: 0.101
  22. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids. 1999 May-Jun; 60(5-6):411-20.
    View in: PubMed
    Score: 0.097
  23. Weight Loss Pharmacotherapy: Brief Summary of the Clinical Literature and Comments on Racial Differences. Ethn Dis. 2015 Nov 05; 25(4):511-4.
    View in: PubMed
    Score: 0.076
  24. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015 Sep 01; 66(9):1050-67.
    View in: PubMed
    Score: 0.075
  25. Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):47-53.
    View in: PubMed
    Score: 0.066
  26. Cardiovascular risk factors, clustering and complications in overweight young men. Med Sect Proc. 1992; 107-15.
    View in: PubMed
    Score: 0.058
  27. Comparative effects of overweight on cardiovascular risk in younger versus older men. Am J Cardiol. 1991 Feb 01; 67(4):248-52.
    View in: PubMed
    Score: 0.055
  28. Prehypertension: an opportunity for a new public health paradigm. Cardiol Clin. 2010 Nov; 28(4):561-9.
    View in: PubMed
    Score: 0.054
  29. Does dark chocolate have a role in the prevention and management of hypertension?: commentary on the evidence. Hypertension. 2010 Jun; 55(6):1289-95.
    View in: PubMed
    Score: 0.052
  30. Prehypertension: should we be treating with pharmacologic therapy? Ther Adv Cardiovasc Dis. 2008 Aug; 2(4):305-14.
    View in: PubMed
    Score: 0.046
  31. Differences in cardiovascular disease mortality associated with body mass between Black and White persons. Am J Public Health. 2008 Jan; 98(1):63-6.
    View in: PubMed
    Score: 0.044
  32. Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):783-9.
    View in: PubMed
    Score: 0.043
  33. Age and race impact the association between BMI and CVD mortality in women. Public Health Rep. 2007 Jul-Aug; 122(4):507-12.
    View in: PubMed
    Score: 0.042
  34. Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci. 2005 Jun; 329(6):276-91.
    View in: PubMed
    Score: 0.037
  35. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci. 2005 Jun; 329(6):292-305.
    View in: PubMed
    Score: 0.037
  36. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
    View in: PubMed
    Score: 0.036
  37. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep. 2003 Jun; 5(3):247-54.
    View in: PubMed
    Score: 0.032
  38. Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster. J Hypertens. 2002 Jun; 20(6):1215-21.
    View in: PubMed
    Score: 0.030
  39. Strategies for cardiovascular disease prevention: importance of public and community health programs. Ethn Dis. 1998; 8(2):228-39.
    View in: PubMed
    Score: 0.022
  40. The impact of metabolic syndrome on metabolic, pro-inflammatory and prothrombotic markers according to the presence of high blood pressure criterion. Clinics (Sao Paulo). 2013 Dec; 68(12):1495-501.
    View in: PubMed
    Score: 0.017
  41. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012 Oct 02; 60(14):1271-7.
    View in: PubMed
    Score: 0.015
  42. Potential deleterious impact of dietary salt restriction on cardiovascular risk factors. Klin Wochenschr. 1991; 69 Suppl 25:45-50.
    View in: PubMed
    Score: 0.014
  43. Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol. 2003 Dec 01; 92(11):1335-9.
    View in: PubMed
    Score: 0.008
  44. Borderline hypertension. Prim Care. 1983 Mar; 10(1):99-113.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.